Related Experiment Videos
Cyclosporine--lessons from the first 20 years.
1Columbia University Department of Pathology, New York, NY 10032, USA. rc238@columbia.edu
Transplantation Proceedings
|March 26, 2004
Summary
Cyclosporine significantly improved long-term graft survival rates in organ transplantation. However, due to its nephrotoxicity, personalized immunosuppression using immunologic tests is now advocated to minimize drug use.
Area of Science:
- Transplantation immunology
- Nephrology
- Immunosuppressive therapy
Background:
- Cyclosporine revolutionized organ transplantation, dramatically increasing long-term graft survival rates.
- Pre-cyclosporine era graft survival rates at 5, 10, and 20 years were 35%, 22%, and 20% respectively.
- Post-cyclosporine era survival rates improved significantly to 75%, 60%, and 45% at the same time points.
Purpose of the Study:
- To highlight the impact of cyclosporine on graft survival.
- To address the nephrotoxicity associated with calcineurin inhibitors like cyclosporine.
- To advocate for a shift towards tailored immunosuppression strategies.
Main Methods:
- Review of historical graft survival data from the pre-cyclosporine and cyclosporine eras.
- Discussion of the nephrotoxic side effects of calcineurin inhibitors.
- Proposal of utilizing immunologic tests for personalized immunosuppression.
Main Results:
- Cyclosporine-based immunosuppression markedly enhanced long-term graft survival.
- Nephrotoxicity remains a significant concern with calcineurin inhibitors.
- Immunologic testing allows for quantitative and qualitative assessment of immune cells.
Conclusions:
- While cyclosporine improved transplant outcomes, its nephrotoxicity necessitates alternative strategies.
- Tailoring immunosuppression based on immunologic monitoring can reduce drug exposure.
- Minimizing immunosuppression through personalized approaches is crucial for long-term patient and graft health.